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PARK2 is a gene implicated in disease states with
opposing responses in cell fate determination, yet
its contribution in pro-survival signaling is largely un-
known. Here we show that PARK2 is altered in over a
third of all human cancers, and its depletion results in
enhanced phosphatidylinositol 3-kinase/Akt (PI3K/
Akt) activation and increased vulnerability to PI3K/
Akt/mTOR inhibitors. PARK2 depletion contributes
to AMPK-mediated activation of endothelial nitric
oxide synthase (eNOS), enhanced levels of reactive
oxygen species, and a concomitant increase in
oxidized nitric oxide levels, thereby promoting the
inhibition of PTEN by S-nitrosylation and ubiquitina-
tion. Notably, AMPK activation alone is sufficient
to induce PTEN S-nitrosylation in the absence of
PARK2 depletion. Park2 loss and Pten loss also
display striking cooperativity to promote tumorigen-
esis in vivo. Together, our findings reveal an impor-
tant missing mechanism that might account for
PTEN suppression in PARK2-deficient tumors, and
they highlight the importance of PTENS-nitrosylation
in supporting cell survival and proliferation under
conditions of energy deprivation.Molecular Cell 65, 999–1013, M
This is an open access article undINTRODUCTION
Cell homeostasis is achieved through an orchestrated balance of
cell signaling interactions that dictate the likelihood of a cell to
escape from normal growth restraints or be eliminated from
the replicative pool, resulting in cell death. Cancer is a group of
diseases that are due to escape from cell death control, while
Parkinson’s disease (PD) portrays a disease that results from
accelerated cell death. It would seem unlikely that these dis-
eases are related, yet there is increasing evidence to suggest
that a subset of PD susceptibility genes are also associated
with cancer (Ong et al., 2014).
PARK2 was originally identified as a gene associated with the
pathogenesis of familial PD in early-onset autosomal recessive
juvenile parkinsonism (Kitada et al., 1998). It has been reported
to be mutated in as high as 77% of PD patients with an age of
onset of <20 years, but only in 3% of patients with an age of
onset of >30 years (L€ucking et al., 2000). Subsequently, it has
been linked to a wide range of disorders, including leprosy
(Mira et al., 2004), autism (Glessner et al., 2009), type 2 diabetes
mellitus (Wongseree et al., 2009), Alzheimer’s disease (Burns
et al., 2009), cerebellar ataxia (Periquet et al., 2003), resistance
to intracellular pathogen infections (Manzanillo et al., 2013),
and cancer, where it is somatically deleted in a wide spectrum
of tumor types (Bernardini et al., 2016). PARK2 is a bona fide
haploinsufficient tumor suppressor, as depletion of a single
PARK2 allele significantly increases adenoma developmentarch 16, 2017 ª 2017 The Authors. Published by Elsevier Inc. 999
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Genetic Landscape of PARK2 Copy Number and mRNA Expression across Human Cancers
(A) Frequencies of PARK2 deletion from 9,863 primary tumors across 28 different cancer types. Colored bars describe the percentage of tumor samples showing
focal deletion (dark blue), overall deletion (light blue), and diploid/no focal gain (gray).
(B) Frequencies of relative fold change of PARK2 mRNA underexpression between cancerous and corresponding normal tissues (R0.5- and R1-log2-fold
change in tumor versus normal). The analysis was performed on 13,481 specimens from 25 different cancer types (mRNA downregulatedR1-log2-fold change,
(legend continued on next page)
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and polypmultiplicity in ApcMin/+ mice (Poulogiannis et al., 2010).
PARK2 loss also renders mice more susceptible to hepatocellu-
lar (Fujiwara et al., 2008) and g-irradiation-induced carcinomas
(Zhang et al., 2011), while ectopic PARK2 expression mitigates
cell proliferation in colorectal, glioma, breast, hepatocellular,
and non-small-cell lung cancer cells (Lin et al., 2015; Picchio
et al., 2004; Poulogiannis et al., 2010; Tay et al., 2010; Veeriah
et al., 2010; Wang et al., 2004; Yeo et al., 2012).
The PARK2 gene encodes the E3 ubiquitin ligase Parkin,
which mediates the ubiquitination of a number of substrate pro-
teins, leading to their proteasomal degradation (Dawson and
Dawson, 2010). Its activities go beyond the degradative ubiquiti-
nation, and it is implicated in the regulation of multiple cellular
processes, including stress response, mitochondrial biogenesis,
and stability of G1/S cyclins (Corti and Brice, 2013; Gong et al.,
2014). Although the underlying mechanisms by which patho-
genic PARK2 mutations contribute to PD are not entirely under-
stood, mitochondrial dysfunction is considered to play a central
role in stress-induced neuronal cell death associated with the
pathogenesis of this disorder. Increased oxidative and nitrosa-
tive stress is a common phenomenon in both PD and cancer;
hence, it is imperative to identify the molecular pathways under-
lying the functional contribution of PARK2 depletion in these
processes.
Compelling evidence shows that cancer cells utilize multiple
pathways, including the phosphatidylinositol 3-kinase/Akt
(PI3K/Akt) signaling pathway, to enhance their survival and pre-
vent apoptosis under metabolic stress conditions (Trachootham
et al., 2008). Importantly, PARK2 has previously been associated
with the activation of the Akt pathway (Fallon et al., 2006; Lin
et al., 2015; Yeo et al., 2012); however, the mechanistic evidence
behind its functional contribution is unclear. One study showed
that Parkin interacts with and ubiquitinates Eps15 to delay the
internalization and degradation of its adaptor protein epidermal
growth factor receptor (EGFR), thereby promoting PI3K/Akt
signaling (Fallon et al., 2006), while a more recent study suggests
that Parkin directly interacts with and promotes the ubiquitination
of EGFR, leading to diminished activation of EGF-induced PI3K/
Akt signaling (Lin et al., 2015). These data highlight the need for
further investigation of the molecular events underlying the role
of PARK2 depletion in PI3K/Akt-mediated cellular survival.
In this study, we identified PTEN as an important mediator
behind the functional contribution ofPARK2 depletion in the acti-
vation of the PI3K/Akt pathway, and we further characterized its
pivotal role in the tumor suppressor function of PARK2 in vitro
and in vivo. Additionally, our results reveal an important missing
piece in the dynamic signaling and metabolic network connect-
ing AMPK with Akt activation in the absence of mTORC1-S6K-red; mRNA downregulatedR0.5-log2-fold, yellow; no loss of mRNA expression,
from the TCGA database.
(C) PARK2 mRNA expression in subgroups of primary GBMs of different ploidy
(Hetloss, n = 158), and homozygous deletion (Homdel, n = 19) (p = 3.5 3 107, o
(D) Representative IHC staining intensities of PARKIN protein expression across
(E) Kaplan-Meier survival plots of glioma cancer patients stratified by tumors bear
PARK2Diploid two copies, n = 149), low versus intermediate PARK2mRNA expre
92; PARK2 Intermediate <two times lower or higher than log2 median expression
(from left to right: p = 0.032, p = 4 3 104, p = 0.01, log-rank test).
See also Figure S1 and Tables S1 and S2.dependent negative feedback loopmechanisms (Efeyan and Sa-
batini, 2010), demonstrating a compensatory survival mecha-
nism for cancer cells under conditions of energy deprivation.
RESULTS
PARK2 Genomic and Gene Expression Profiling across
Human Cancers
We examined the degree of PARK2 deletion in the largest up-to-
date collection of The Cancer Genome Atlas (TCGA), assembling
data from 9,863 primary tumors from 28 different tumor types
(Table S1). Focal deletions (Figure 1A, dark blue) of the PARK2
geneweremost commonly found in colorectal (21%) and ovarian
(25%) carcinomas, while a strikingly high number of tumors,
including lung adenocarcinomas, melanomas, bladder, ovarian,
and pancreatic, had an overall >40% DNA copy number (DCN)
loss of the PARK2 gene (both focal deletion [Figure 1A, dark
blue] and as part of whole or part chromosome arm losses [Fig-
ure 1A, light blue]). Cholangiosarcomas (CHO) showed a stag-
gering 69% (25/36) rate of overall PARK2 deletions. In parallel,
we also examined the degree of PARK2 mRNA decrease be-
tween cancer and corresponding normal tissues from a total
number of 13,481 specimens, studied in 127 published microar-
ray datasets (Table S2), covering 25 tumor types. Notably, there
were many cancer types, including gliomas, cervical, and kidney
carcinomas, with not the highest frequency of overall PARK2
deletion (<40%) but with widespread (up to 69%) decrease or
loss of its mRNA expression compared to their normal counter-
parts (Figures 1B and S1A; >1-log2-fold [red] or >0.5-log2-fold
[red and yellow]). Vice versa, there were some tumor types,
e.g., ovarian cancer, where PARK2 deletion was found in
>60% of the cases, yet only a small fraction were reported to
have lowPARK2mRNA expression. This reflects in part the strin-
gent criteria we used to report tumor types with >0.5-fold
changes in mRNA expression compared to their normal counter-
parts, but also that the majority (>90%) of PARK2 deletions
across all tumor types are heterozygous and, hence, less likely
to cause a marked reduction in PARK2 mRNA expression.
As high as two-thirds of glioma tumors had significantly
reduced levels of PARK2 mRNA expression compared to their
corresponding normal tissues (Figure 1B). We plotted the
distribution of PARK2 expression, across different subgroups of
gliomas reminiscent of distinct neural cell types, to show that
PARK2 is significantly downregulated irrespective of the histolog-
ical origin of this tumor type (Figure S1B). To identify relationships
between PARK2 DCN and mRNA expression levels, we plotted
the distribution of its expression across subgroups of glio-
blastomas (GBMs) with different PARK2 DCN. PARK2 mRNAgray). The putative DCN and mRNA expression data for PARK2 were retrieved
status, ranging from gain (n = 24) to diploid (n = 376), heterozygous deletion
ne-way ANOVA).
61 GBM specimens.
ing PARK2 deletion versus retention (left: PARK2 Deleted%1.8 copies, n = 24;
ssion (middle: PARK2 LowRtwo times lower than log2median expression, n =
, n = 251), and positive versus negative IHC PARKIN protein expression (right)
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expression was progressively lower across the different sub-
groups of PARK2 ploidy status (Figure 1C). To assess the prog-
nostic significance of this gene across different types of genetic
alteration, we also performed survival analysis between sub-
groups of patients with GBM, divided based on different molecu-
larmarkers of thePARK2 gene. Interestingly, loss ofPARK2 at the
DNA, mRNA, and protein levels (Figure 1D) all correlated with
significantly poorer survival in patients with GBM (Figure 1E). Of
note,PARK2 expressionwas also associatedwith poorer survival
in patients with breast and lung adenocarcinomas (Figures S1C
and S1D). Collectively, our data demonstrate that PARK2 is
altered in over a third of all human cancers. Its widespread loss
or decrease across many molecular biomarker indicators (DNA,
mRNA, and protein) significantly correlates with poorer survival,
offering great prognostic and predictive value for clinical practice.
PARK2 Regulates the Activation of the PI3K/Akt
Pathway
The PI3K/Akt pathway is the single most frequently altered
signaling cascade across all the tumor types, with recurrent
PARK2 deletions and mRNA loss/reduction (Yuan and Cantley,
2008). Activation of the PI3K/AKT/mTOR pathway has also
been associated with significantly poorer survival across many
solid tumors (Ocana et al., 2014). To investigate whether activa-
tion of this pathway is inherently associated with loss of the
PARK2 gene, we stably expressed two independent hairpins tar-
geted against PARK2 in HCT116 cells. Cells with PARK2 knock-
down exhibited a pronounced increase in Akt phosphorylation
compared to control GFP knockdown cells (Figure 2A). Stauro-
sporine is a protein kinase inhibitor that can induce apoptosis
across many different cell types, and Akt hyperactivation has
been shown to attenuate sensitivity to staurosporine-induced
cell death (Mookherjee et al., 2007). We showed that PARK2
depletion augmented resistance to staurosporine-induced cell
death (Figure 2B), and this was consistent with significantly
lower apoptotic response, as indicated by caspase-3/7 activity
(Figure 2C).
Identification of candidate biomarkers that predict responsive-
ness to specific signaling cascade inhibitors is increasingly
important in the era of personalized medicine. Accordingly, we
assessed the role of PARK2 knockdown to the inhibition of
various signaling nodes across the PI3K/Akt/mTOR and MAPK
pathways. PARK2 depletion rendered cells more sensitive to in-
hibitors of PI3K (BKM120 and BEZ235), Akt (MK2206), and
mTOR (BEZ235, Rapamycin, and Torin), but it decreased the
effectiveness of MEK inhibitors PD0325901 and GSK1120212
(Figures 2D, 2E, S2A, and S2B). Taken together, these data
suggest that PARK2 loss contributes in the activation of Akt
signaling and the dependence of cells on this pathway, suggest-
ing that PARK2 deficiency could be used as a biomarker of effi-
cacy and favorable clinical response to inhibitors of the PI3K/
Akt/mTOR pathway.
PARK2 Suppresses Akt Activation and Tumorigenicity in
PTENWild-Type but Not PTEN Mutant Cells
To explore the significance of Akt activation in the molecular
mechanisms that PARK2 may contribute to tumor suppression,
we tested the effect of PARK2 overexpression in PTENwild-type1002 Molecular Cell 65, 999–1013, March 16, 2017(WT) (HCT116 PTEN+/+ and H1299) and PTEN mutant (PC3 and
HCT116 PTEN/) cell line models. Ectopic expression of
PARK2 led to the inhibition of Akt phosphorylation in HCT116
cells (Figure 3A). Importantly, we showed that PARK2 overex-
pression led to the inhibition of Akt activation upon growth factor
stimulation in PTEN WT H1299 cells (Figure 3B), but not in the
PTEN mutant PC3 cells (Figure 3C). This reduction in Akt phos-
phorylation was also apparent when we ectopically expressed
PARK2 at levels near the endogenous Parkin levels expressed
in H460 cells, for both the EGFR WT (H1299) and EGFR null
(SW620) cells (Figures S2C and S2D). Unlike in parental
PTEN+/+ HCT116 cells, overexpression of PARK2 did not reduce
Akt phosphorylation in isogenic PTEN/ HCT116 cells (Fig-
ure S2E), further supporting a role for PTEN in PARK2-mediated
regulation of PI3K/Akt signaling.
Akt has been shown to play a central role in promoting growth
factor-mediated cell proliferation and migration (Manning and
Cantley, 2007). Given that PARK2 inhibits Akt phosphorylation,
we sought to investigate its functional contribution in suppress-
ing some of the cellular functions mediated by Akt activation.
HCT116 PTEN+/+ and H1299 cells exhibited a pronounced
reduction in both cell proliferation (Figure 3D) and cell migration
(Figure 3E) upon PARK2 overexpression. However, this was not
true for the PTEN mutant PC3 and isogenic PTEN/ HCT116
cells that showed no effect compared to control empty vector
(EV)-expressing cells. No effect on cell proliferation and migra-
tion was also observed when overexpressing the E3-Ligase
dead C431S Parkin mutant in both PTEN WT and mutant cells
(Figures S2F–S2H).
To investigate the tumor suppressor effect of PARK2 in vivo,
we retro-orbitally injected luciferase-labeled H1299 cells overex-
pressing EV or human PARK2. Ectopic expression of PARK2
significantly mitigated the formation of lung metastases (Figures
3F–3I) in NOD/SCID mice. The luciferase activity in cells
expressing the PARK2 gene was reduced on both weeks 3
and 4 post-injection (Figures 3F and 3G), and this was consistent
with significantly lower number and smaller size of lung metasta-
ses, as histopathologically evaluated with H&E-stained sections
(Figures 3H and 3I). These data show that suppression of Akt
activation plays a central role in the tumor suppressor function
of PARK2 and that the mutational status of PTEN determines
the functional contribution of PARK2 loss in Akt-mediated cell
proliferation and migration.
PARK2 Depletion Suppresses PTEN Protein Levels and
Activity
To further investigate the role of PTEN in PARK2-mediated regu-
lation of the PI3K/Akt pathway, we performed PARK2 knock-
down analysis in cell lines with abundant Parkin but either WT
PTEN present (HCT116 and H460) or absent (PC3 and U138).
In line with our overexpression studies, PARK2 knockdown
induced Akt phosphorylation in HCT116 and H460 cells, but
not in PC3 or U138 cells (Figures 4A, S3A, and S3B) or in the
isogenic PTEN null HCT116 (Figure 4B) and MCF10A cells
(Figure S3C). Most importantly, PARK2 depletion led to a
>30% reduction in PTEN protein levels across all PTEN WT
cell lines (Figures 4A, 4B, and S3C), and this observation was
confirmed in CRISPR/Cas9-mediated PARK2 knockout H460
Figure 2. PARK2 Depletion Contributes to the Activation of the PI3K/Akt Pathway
(A) Immunoblotting analysis of HCT116 cells stably transfected with control GFP (shGFP) or PARK2 (shPARK2_1 and shPARK2_2) lentiviral hairpins.
(B andC) Shown is the (B) CellTiter 96 AQueousNon-Radioactive Cell Proliferation (MTS) assay and (C) caspase-3/7 activity assay of shGFP or shPARK2HCT116
cells, following treatment with increasing concentrations of staurosporine (50 and 100 nM) for 1 hr (MTS assay, p = 0.001 for 50-nM and p = 0.0008 for 100-nM
treatment; caspase-3/7 assay, p = 0.043 for 50-nM and p = 0.036 for 100-nM treatment).
(D) Immunoblotting analysis of shGFP and shPARK2HCT116 cells following treatment with the indicated compounds: 1 mMBKM (NVP-BKM120) or 500 nMBEZ (NVP-
BEZ235) for 24 hr, 500 nMMK (MK 2206) for 4 hr, 100 nMRapa (Rapamycin) or Torin for 2 hr, 100 nMPD0 (PD0325901) for 1 hr, or 10 nMGSK (GSK1120212) for 6 hr.
(E) Drug dose-response curves of shGFP and shPARK2HCT116 cells treatedwith the indicated compounds for 24 hr (NVP-BKM120, p = 0.014; NVP-BEZ235, p =
9.283 105; MK 2206, p = 13 104; Rapamycin, p = 1.453 1011; Torin, p = 6.733 1010; PD0325901, p = 0.02; and GSK1120212, p = 0.03, two-way ANOVA).
Data are represented as mean ± SEM (*p < 0.05 and **p < 0.01, two-tailed t test).
See also Figure S2.
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Figure 3. PARK2Overexpression Suppresses Akt Activation andMitigates Cell Proliferation andMigration in PTENWild-Type, but Not PTEN
Mutant, Cells
(A–C) Immunoblotting analysis of (A) HCT116 cells transfected with vector only or vector encoding WT PARK2, (B) PTENWT H1299 cells, and (C) PTENmutant
PC3 cells expressing vector only or vector encoding WT PARK2 following 10% fetal bovine serum (FBS) stimulation. Cells were serum-starved for 24 hr prior to
FBS stimulation.
(D and E) Shown are the (D) cell proliferation (HCT116PTEN+/+, p = 0.002; HCT116 PTEN/, p = 0.99; H1299, p = 3.43 105; and PC3, p = 0.66, two-way ANOVA)
and (E) cell migration assays of PTENWT (HCT116 PTEN+/+ and H1299) and PTEN-deficient (HCT116 PTEN/ and PC3) cells expressing vector only or vector
encoding WT PARK2 (HCT116 PTEN+/+, p = 8.1 3 104; HCT116 PTEN/, p = 0.99; H1299, p = 4.7 3 103; and PC3, p = 0.68).
(F) BLI images of NOD/SCID mice retro-orbitally injected with luciferase-labeled H1299 cells expressing EV or human PARK2. Images were taken at 3 and
4 weeks post-injection (W3 and W4) to assess for luciferase-expressing lung metastases.
(G) Quantification of BLI intensities on weeks 3 and 4 post-injection (EV, p = 0.02; and human PARK2, p = 0.54). The lungs were then dissected from the mice for
H&E staining.
(H) Scatterplot indicating that overexpression of PARK2 significantly mitigated the formation of lung metastases in NOD/SCID mice (p = 0.006).
(I) Representative H&E staining of lung sections 4 weeks post-injection to highlight significantly more and larger size metastatic tumor lesions in the mice injected
with vector only or with vector encoding WT PARK2 H1299 cells. Data are represented as mean ± SEM (n.s., not significant; *p < 0.05 and **p < 0.01, two-tailed
t test).
See also Figure S2.cells (Figure S3D). Previous studies with hypomorphic Pten
allelic series of mice have shown that even subtle reductions in
Pten protein levels can have dramatic consequences in cancer
progression (Trotman et al., 2003). PTEN is regulated in cancer
at the transcriptional, post-transcriptional, and post-transla-
tional levels (Song et al., 2012).
To gain further insight into this regulation by PARK2, we per-
formed qPCR analysis of both PARK2 and PTEN following lentivi-
ral knockdown of PARK2, and we showed that PARK2 depletion
does not affect PTENmRNA levels (Figures 4C and S3E). Impor-1004 Molecular Cell 65, 999–1013, March 16, 2017tantly, PARK2 depletion resulted in a significantly lower PTEN
enzymatic activity (Figures 4D and S3F) and higher levels of
PI(3,4,5)P3 and PI(3,4)P2 in cells (Figure 4E), further supporting
the functional contribution of PTEN in PARK2-mediated regulation
of the PI3K/Akt pathway. Moreover, we were struck to observe a
reciprocal correlation between Parkin and PTEN protein expres-
sion across ten breast cancer cell lines that have previously
been reported to be WT for PTEN (Figure S3G) (Saal et al., 2008).
In view of our findings, we speculated that suppression of
PTEN protein levels by PARK2 depletion might be regulated by
Figure 4. PARK2 Depletion Contributes to Akt Activation in a PTEN-Dependent Manner
(A and B) Immunoblotting of shGFP and shPARK2-expressing PTEN WT HCT116parental, H460 or PTENmutant: PC3, U138 cells (A) and isogenic PTENWT and
NULL HCT116 cells (B).
(C) Real-time qPCR for PARK2 and PTEN on mRNA isolated from shGFP and shPARK2 HCT116 cells (PARK2 qPCR, p = 0.001; and PTEN qPCR, p = 0.44).
(D and E) Shown are the (D) PTEN activity assay (p = 0.015) and (E) phosphoinositide PI(3,4,5)P3 and PI(3,4)P2 levels between shGFP and shPARK2 HCT116 cells
(PI(3,4,5)P3, p = 0.002; and PI(3,4)P2, p = 0.015). PTEN was ectopically expressed equally between cells.
(F) Immunoblotting of shGFP and shPARK2 HCT116 cells with or without treatment with 10 mMMG132 for 6 hr. Data are represented as mean ± SEM (n.s., not
significant; *p < 0.05 and **p < 0.01, two-tailed t test).
See also Figures S3 and S4.proteasome-mediated protein degradation. Indeed, treatment
with proteasome inhibitor MG132 led to an overall increase in
PTEN protein levels and no significant difference between GFP
and PARK2 knockdown cells (Figures 4F and S3H). Taken
together, these results show that PARK2 depletion suppresses
PTEN protein levels and activity, and they raise an interesting hy-
pothesis that, mechanistically, this could be regulated, at least in
part, by ubiquitin proteasome-mediated protein degradation.
Increased Oxidative and Nitrosative Stress upon PARK2
Depletion
Recent evidence shows that Parkin loss leads to a marked
decrease in mitochondrial biogenesis (Stevens et al., 2015). To
investigate the role of PARK2 depletion in cellular metabolism,
we initially measured the effect of knocking down PARK2
expression on the oxygen consumption rate (OCR) of shGFP-
and shPARK2-expressing cells, in the presence or absence of
different mitochondrial stress inhibitors, using the Seahorse
XFe96 Flux Analyzer. Notably, PARK2 depletion resulted in amarked decrease in basal, maximal, mitochondrial, and non-
mitochondrial respiration (Figures 5A, 5B, S4A, and S4B).
We next explored the effects of PARK2 depletion on cellular
metabolism by performing targeted metabolomic analysis.
Consistent with lower OCR levels, PARK2 knockdown cells
showed a significant decrease in ATP levels (Figure 5C) and a
concomitant activation of AMPK (Figures 5D and S4C), accom-
panied by the inhibition of mTORC1 signaling (Figures S4D and
S4E). PARK2 depletion also caused a reduction across many
of the cofactors that contribute in nitric oxide (NO) biosynthesis,
involving the conversion of L-arginine to L-citrulline (Figures 5E
and 5F). Importantly, although all the anaplerotic substrates for
NO synthesis were detected to be lower in the PARK2 knock-
down cells, L-citrulline levels were not significantly lower.
Although other interpretations are possible, these results are
consistent with a model in which NO synthase (NOS) is activated
due to the loss of PARK2, such that the substrates for NOS are
being consumed at a high rate while the product of NOS L-citrul-
line is maintained at a relatively constant level.Molecular Cell 65, 999–1013, March 16, 2017 1005
Figure 5. The Role of PARK2 Depletion in Cellular Metabolism and AMPK-Mediated eNOS Activation
(A–D) Shown are the (A) Seahorse analysis of OCR following sequential injection of oligomycin, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP),
and antimycin A/rotenone (n = 6); (B) the OCR of basal (p = 0.016), maximal (p = 0.003), and non-mitochondrial respiration (p = 0.037); (C) the relative ATP levels
(p = 0.02); and (D) immunoblotting analysis between shGFP and shPARK2 HCT116 cells.
(E) Schematic representation of NO biosynthesis involving the conversion of L-arginine into L-citrulline by NOS in the presence of cofactors, including NADPH,
FAD, FMN, CaM, O2, and BH4.
(F) Relative abundance of metabolites involved in NO biosynthesis following PARK2 knockdown in HCT116 cells (FAD, p = 0.002; FMN, p = 0.011; NADP,
p = 0.025; NADPH, p = 0.019; Arginine, p = 0.063; and Citrulline, p = 0.24).
(G–K) Shown are the (G) relative NOS activity (p = 0.017), (H) oxidized NO levels (p = 5.13 104), (I) NADP/NADPH levels (p = 0.013), (J) ROS levels following 2-hr
menadione treatment (20 mM) (p = 0.006), and (K) GSH/GSSG levels between shGFP and shPARK2 HCT116 cells (p = 0.008).
(L and M) Immunoblotting analysis of (L) shGFP and shPARK2 HCT116 cells, with or without treatment with 5 mM GSH-MEE for 72 hr, and (M) HCT116 cells
following treatment with the indicated concentrations (0–20 mM) of the allosteric AMPK activator 991 for 5 hr. Cells were serum-starved for 2 hr prior to 991
treatment. Data are represented as mean ± SEM (n.s., not significant; *p < 0.05 and **p < 0.01, two-tailed t test).
See also Figure S4.Indeed, consistent with this model, we measured the NOS ac-
tivity and oxidized NO (NO2 +NO3) levels, andwe found that they
are significantly higher in PARK2 knockdown cells (Figures 5G,
5H, and S4F). The latter also showed an overall increase in1006 Molecular Cell 65, 999–1013, March 16, 2017NADP/NADPH ratio (Figure 5I), higher reactive oxygen species
(ROS) levels upon menadione treatment (Figures 5J and S4G),
and lower reduced/oxidized glutathione (GSH/GSSG) levels
(Figures 5K and S4H) compared to GFP control knockdown
cells. Importantly, besides its function as a regulator of cellular
redox status, GSH has a crucial role in modulating NO reactivity
(Aquilano et al., 2014). NO as a free radical is a poor oxidant,
hence, NO-dependent cysteine oxidation primarily occurs in
the presence of oxygen or high ROS (Broniowska and Hogg,
2012). Of note, we showed that GSH-MEE (reduced ethyl ester)
treatment restored the suppression in PTEN protein levels
observed in PARK2 knockdown cells (Figures 5L and S4I), while
L-Buthionine-sulfoximine (BSO) treatment further enhanced the
reduction in PTEN (Figure S4J). In addition, the activity of
PTEN in PARK2 knockdown cells in the presence of DTT was
comparable to the shGFP cells without the DTT pre-incubation
(Figure S4K), reinforcing the conclusion that the inhibition of
PTEN is generated by a redox-dependent modification of
cysteine residues.
Mitochondrial dysfunction and oxidative stress are well-
recognized mechanisms leading to the activation of AMPK that
can directly phosphorylate endothelial NOS (eNOS) to increase
its catalytic activity (Schulz et al., 2009). In line with this, we
showed that PARK2 knockdown (Figure S4L) or allosteric activa-
tion of AMPK following treatment with the small molecule
activator 991 (Figure 5M) led to an increase of eNOS phosphor-
ylation and a reduction in PTEN protein levels. Of note, this
reduction in PTEN protein levels and concomitant increase in
Akt activation that were observed in 991-treated cells were
decreased upon co-treatment with the NO scavenger carboxy-
PTIO (cPTIO) (Figure S4M). Collectively, these results demon-
strate that PARK2 depletion leads to mitochondrial dysfunction,
high eNOS activity that is mediated, at least in part, by AMPK
activation, and high ROS levels that together coordinate efficient
NO oxidation.
PARK2 Depletion Promotes PTEN S-Nitrosylation and
Ubiquitination
High NO production exerts a pleiotropic range of biological func-
tions that are regulated, in part, by a post-translational redox-
mediated modification known as S-nitrosylation of protein
cysteine residues. PTEN has previously been identified as a
target of such modification (Kwak et al., 2010; Numajiri et al.,
2011) that leads to the inhibition of its enzymatic activity and
downstream activation of Akt signaling. In view of our previous
findings, we speculated that PARK2 depletion-mediated activa-
tion of the Akt pathway might be regulated by PTEN S-nitrosyla-
tion. Indeed, PARK2 depletion resulted in a marked induction of
PTEN S-nitrosylation (SNO-PTEN), as indicated both by immu-
noblotting immunoprecipitated PTENwith the anti-S-nitrosocys-
teine antibody (Figures 6A and S5B) and by measuring the
release of NO from S-nitrosothiol of recombinant PTEN using
the quantitative fluorescent 2,3-diaminonaphthalene (DAN)
assay (Figures 6B and S5C). Interestingly, PTEN S-nitrosylation
has previously been shown to promote its ubiquitination (Kwak
et al., 2010), which could also explain the reduction in total
PTEN protein levels and rescue following treatment with the pro-
teasome inhibitor MG132 (Figures 4F and S3H). We performed
an in-cell PTEN ubiquitination assay and showed that PARK2
depletion resulted in a marked increase in PTEN ubiquitination,
with or without pre-treatment with MG132 for 6 hr (Figures 6C,
6D, and S5D). Consistent with enhanced PTEN ubiquitination,we also found an increased abundance of conjugated ubiquitin
(ub) on PTEN in PARK2 knockdown HCT116 cells expressing
HA-Ubiquitin (Figure S5A). An increase in phospho-Akt levels
was observed in MG132-treated cells even in the absence of
PARK2 knockdown (Figure 6C), perhaps reflecting the increase
in ub conjugates and PTEN ubiquitination (Figure 6D) resulting
from proteasome inhibition.
Cysteine (Cys-83) has previously been identified as the critical
cysteine thiol group within PTEN’s phosphatase domain that is
predominantly targeted for S-nitrosylation, and, in line with this,
C83S mutant PTEN is resistant to modification (Numajiri et al.,
2011). Accordingly, we overexpressed WT and C83S mutant
PTEN in the presence or absence ofPARK2 lentiviral small hairpin
RNA (shRNA) to show that the C83S mutant was completely
devoid of S-nitrosylation and rescued Akt activation in PARK2
knockdown cells (Figure 6E). Importantly, since the activation of
eNOS is also regulated by Akt-dependent phosphorylation
(Dimmeler et al., 1999), our observation raised a dilemma as to
whether the contribution of PARK2 depletion to PTEN inhibition
by S-nitrosylation is the consequence of Akt activation or is regu-
lated via AMPK-mediated activation of eNOS independently of
PI3K-Akt. To address this, we treated shGFP- and shPARK2-ex-
pressing HCT116 with the Akt inhibitor MK-2206 to show that
inhibition of Akt activity does not rescue S-nitrosylation of
PTEN (Figure S5E) nor the increased NO levels in PARK2 knock-
down cells (Figure S5F). On the contrary, small interfering RNA
(siRNA)-mediated downregulation of AMPK (AMPK a1 and a2)
led to a reduction in PTEN S-nitrosylation in PARK2 knockdown
cells (Figure 6F), further supporting the mechanistic implication
of AMPK in PARK2-mediated activation of Akt.
To determine the importance of AMPK activation to trigger
PTEN S-nitrosylation, we tested if AMPK activation alone is
sufficient to induce this modification in the absence of PARK2
depletion. Activation of AMPK following 991 treatment, glucose
deprivation, or oligomycin treatment all led to a marked increase
in PTEN S-nitrosylation (Figure 6G), identifying a functional
cross-talk between AMPK and Akt activation.
To better understand the physiological importance of PTEN
S-nitrosylation in the proliferation and survival of cells under
conditions of metabolic stress, we performed clonogenic as-
says in PTEN null PC3 cells overexpressing EV, WT, or SNO-
resistant (C83S) PTEN in the presence or absence of the
glycolysis inhibitor 2-Deoxy-D-glucose (2-DG). Although no
significant difference in colony formation was detected in
PTEN WT-overexpressing cells with or without 2-DG treat-
ment, there was a marked reduction (30%) in the number of
colonies following 2-DG treatment in PC3 cells with enforced
expression of the C83S mutant PTEN (Figures S6A–S6C).
Moreover, we compared the half-maximal inhibitory concen-
trations (IC50s) of 2-DG and dichloroacetate (DCA) (PDK inhib-
itor), both of which result in the activation of AMPK in response
to ATP depletion, to show that PC3 cells expressing the C83S
mutant exhibited significantly higher sensitivity to treatment
with these drugs, not evident in PTEN WT-expressing PC3
cells (Figures S6D and S6E). Last but not least, and consistent
with the ability of PARK2 knockdown cells to inactivate WT
PTEN, we showed that shPARK2 cells proliferate significantly
faster than shGFP-expressing cells in the presence of ectopicMolecular Cell 65, 999–1013, March 16, 2017 1007
Figure 6. PARK2 Depletion Leads to Enhanced S-nitrosylation and Ubiquitination of PTEN
(A) Anti-PTEN immunoprecipitates (IP) derived from MYC-tagged-transfected PTEN HCT116 cells expressing GFP or PARK2 shRNA.
(B) Fluorometric measurement of S-nitrosylated PTEN between shGFP and shPARK2 HCT116 cells. SNO-PTEN was assessed by NO release, causing the
conversion of DAN to the fluorescent compound NAT (p = 0.009).
(C and D) Immunoblotting analysis of (C) whole-cell lysates and (D) anti-PTEN immunoprecipitates (IP) derived from HA-ubiquitin (Ub) and Myc-tagged PTEN-
transfected HCT116 cells expressing GFP or PARK2 shRNA. Where indicated, cells were treated with MG132 (10 mM) for 6 hr before collection.
(E–G) Immunoblotting analysis and anti-PTEN immunoprecipitates derived from (E) Myc-taggedWT or C83Smutant PTEN-transfected HCT116 cells expressing
GFP or PARK2 shRNA; (F) WT PTEN-transfected shGFP and shPARK2 HCT116 cells, 48 hr post-transfection with scrambled or AMPK a1 and AMPK a2 siRNAs;
and (G) parental HCT116 treated (or not treated) with the allosteric AMPK activator 991 for 5 hr (20 mM) following 2 hr serum starvation (left) or with 25-mMglucose-
containing DMEM (middle) for 6 hr or with oligomycin (5 mM) for 2 hr. Data are represented as mean ± SEM.
See also Figures S5 and S6.co-expression of WT (Figure S6F), but not C83S mutant, PTEN
(Figure S6G). Taken together, these data demonstrate that
PARK2 depletion contributes to the activation of Akt signaling
through promoting S-nitrosylation and ubiquitination of the
tumor suppressor PTEN. Notably, our data also highlight a pre-1008 Molecular Cell 65, 999–1013, March 16, 2017viously unexplored mechanism contributing to AMPK-medi-
ated activation of PI3K/Akt involving the inhibition of PTEN
by S-nitrosylation, which appears to be critical for the prolifer-
ative capacity and survival of PTEN-proficient cancer cells un-
der conditions of energy stress.
Park2DeletionDramatically Promotes Tumorigenesis in
Pten Heterozygous Knockout Mice
Given the functional contribution of PARK2 depletion in PTEN
inactivation by S-nitrosylation, we performed a bioinformatic
analysis to report the copy number alterations (CNAs) of
PARK2 and PTEN across 995 cancer cell lines of the Cancer
Cell Line Encyclopedia (CCLE) project. We were struck to
identify that almost one-half of cell lines with HET deletion in
PTEN (n = 145/314, 46.2%) also have HET deletion in
PARK2, with the coexistence for loss of heterozygosity
(LOH) at both the PTEN and PARK2 loci being far more
frequent than PTEN (n = 79/314, 25.2%) or PARK2 (n = 119/
344, 34.6%) LOH alone (Figure S7A). We extended this bio-
informatic analysis summarizing the percentage of PARK2
CNAs of primary tumors or cancer cell lines with PTEN LOH
on 1,953 specimens across 13 different cancer types from
the TCGA database to show that there is a strong selection
for PARK2 LOH, when one copy of the PTEN gene is missing
(Figure S7B).
In an effort to study whether Park2 loss further exacerbates
Pten-mediated tumorigenesis in vivo, mice with a targeted
knockout of Park2 exon 3 (Itier et al., 2003) were crossed with
Pten+/ mice (Di Cristofano et al., 1998). The latter were born
viable and developed prostatic intraepithelial neoplasia (PIN),
as well as numerous neoplastic lesions in many organs,
including skin, colon, endometrium, liver, thyroid, and thymus
(Di Cristofano et al., 1998; Podsypanina et al., 1999). Although
Pten+//Park2+/ and Pten+//Park2/ mice showed a similar
spectrum of tumors like the ones detected in Pten+//Park2+/+
mice, they were significantly more tumor prone and exhibited
features reminiscent of mice with a hypomorphic and a
knockout Pten allele (Figure 7A). Park2 loss was associated
with an increased incidence of high-grade PIN and low-grade
prostate adenocarcinoma (Figures 7B and 7D), as well as signif-
icantly higher numbers of solid thyroid adenocarcinomas (Fig-
ure 7C). Most importantly, mice bearing Park2 loss developed
tumor types, including hystiocytic sarcoma, multiple myeloma,
and osteosarcoma in spine (Figures S7C and S7D), that have
not been previously described for the Pten+/ mice. On two
occasions, mice bearing both Park2 and Pten loss developed
malignant pheochromocytomas and thyroid adenocarcinomas
that metastasized to the lung (Figures S7C and S7D). As a
result, Pten+//Park2+/ and Pten+//Park2/ mice showed
significantly poorer survival compared to Pten+//Park2+/+
mice (Figures 7E and 7F), while no difference in relative survival
was found between Pten+//Park2+/ and Pten+//Park2/
mice (Figure S7E).
To further assess the contribution of the proposed model on
the PARK2-mediated inactivation of PTEN in vivo, we performed
immunohistochemical (IHC) analysis of PTEN and phospho-Akt
on tumor sections derived from Pten+/ mice bearing WT, het-
erozygous (HET), or homozygous (HOM) deletion in Park2.
Consistent with reduced PTEN and elevated phospho-Akt
expression observed in the immunoblot analyses, Pten+/ tumor
epithelia bearing one or no copies of Park2 expressed no or low
PTEN protein levels, and they showed significantly higher phos-
pho-Akt staining compared to lesions in Pten+//Park2+/+ mice
(Figures S7F–S7H). Overall, our analysis showed that losses offunction of Park2 and Pten displayed striking cooperativity to
promote tumorigenesis and significantly shorten tumor-free
survival.
DISCUSSION
The PI3K/Akt pathway represents a complex signaling network
that integrates numerous upstream stimuli to regulate diverse
cellular processes, including cell growth, proliferation, survival,
and migration (Manning and Cantley, 2007). Interestingly, the
PARK2 gene is associated with the pathogenesis of disease
states that are characterized by different responses in cell fate
determination; therefore, understanding its functional contribu-
tion in the activation of survival pathways is clearly of immense
clinical benefit.
In this study, we identify a PTEN-mediated role for PARK2
depletion in the activation of the PI3K/Akt pathway. Of note,
recent evidence suggested that PARK2 interacts with EGFR to
promote its ubiquitination, thereby inhibiting Akt activation (Lin
et al., 2015). However, the role of EGFR in PARK2-mediated
activation of PI3K-Akt signaling might be more complex and/or
cell type specific than previously appreciated, as ectopic
PARK2 expression suppresses Akt activation even in EGFR
null SW620 cells.
PTEN is a well-characterized haploinsufficient tumor suppres-
sor (Di Cristofano et al., 1998), yet emerging evidence suggests
that its function goes beyond its tumor suppressor role as a
critical regulator of multiple CNS functions (Ismail et al., 2012).
PTEN loss and subsequent activation of the PI3K/Akt signaling
promotes the activation of mTOR signaling, which is hyperactive
in many cancers (Carracedo and Pandolfi, 2008). Notably, the
inhibition of mTORC1 by rapamycin treatment prevents PD
symptoms in mice bearing a human mutation in the PARK2
gene (Siddiqui et al., 2015). Furthermore, PTEN loss leads to
the downregulation of PINK1 expression (Unoki and Nakamura,
2001), supporting a mechanism to suggest that PARK2
LOH could repress PINK1 through inactivating PTEN and
PINK1 repression could obliterate any residual activity of the
remaining PARK2 allele, by abrogating Parkin translocation to
mitochondria.
An important mode of NO function primarily involves its
reaction with oxygen or ROS and subsequent oxidation to nitro-
gen dioxide (NO2), dinitrogen trioxide (N2O3), or peroxynitrite
(ONOO), which ultimately lead to nitrosative stress and S-ni-
trosylation of target proteins and other biomolecules (Kovacs
and Lindermayr, 2013). Of note, NO signaling and S-nitrosyla-
tion have previously been detected to contribute to PTEN inac-
tivation in neurodegeneration (Kwak et al., 2010), but the role in
cancer has been largely unknown. In this study, we showed that
one of the most common genetic alterations across human
cancers, PARK2 loss, contributes to S-nitrosylation of PTEN,
thereby promoting its ubiquitin-dependent degradation by the
proteasome. We also report that there is a strong selection for
co-occurrence of PARK2 and PTEN LOH in cancer. This sug-
gests that the high incidence of complete IHC loss of PTEN in
PTEN HET tumors could be explained, at least in part, due to
PARK2 LOH, leading to S-nitrosylation and ubiquitination of
the protein encoded from the remaining PTEN allele. In lineMolecular Cell 65, 999–1013, March 16, 2017 1009
Figure 7. In Vivo Role of Park2 Depletion in Pten Heterozygous Knockout Mice
(A) Types and frequencies of hamartomas/adenomas/carcinomas/other neoplasms found in Pten+/ mice with WT, HET, or HOM deletion of Park2.
(B and C) Shown are the (B) frequencies of low- and high-grade prostatic intraepithelial neoplasia (PIN) lesions, prostatic low-grade adenocarcinoma, and (C)
different stages of thyroid adenoma/carcinoma lesions found in Pten+/mice in the presence/absence of monoallelic or biallelic Park2 deletion (prostate lesions,
p = 9.3 3 1012; and thyroid lesions, p = 0.002, chi-square test).
(D) Representative H&E-stained sections of the low- (left) and high-grade (middle) PIN lesions and low-grade adenocarcinoma (right) found inPten+/mice with or
without Park2 deletion. Scale bars, 250 (left and middle) and 500 mm (right).
(E) Kaplan-Meier survival plot of Pten+/ mice bearing WT (red) (n = 21) or HET (blue) (n = 27) Park2 deletion (p = 0.0108, log-rank test).
(F) Kaplan-Meier survival plot of Pten+/ mice bearing WT (red) (n = 21) or HOM (green) (n = 24) Park2 deletion. Both HET and HOM deletions of the Park2 gene
significantly increased the cancer-related mortality of Pten+/ mice (p = 0.0015, log-rank test).
See also Figure S7.with our previous observations (Poulogiannis et al., 2010),
PARK2 has many of the properties of a haploinsufficient tumor
suppressor in that loss of a single Park2 allele exacerbates
tumorigenesis without requiring complete inactivation of the re-
maining allele.
Notably, activation of AMPK alone can trigger a marked
increase in PTEN S-nitrosylation, pointing to a functional
cross-talk between AMPK and Akt activation in the absence
of any mTORC1-dependent negative feedback loop mecha-1010 Molecular Cell 65, 999–1013, March 16, 2017nisms (Efeyan and Sabatini, 2010). This redox-dependent modi-
fication in PTEN is important for supporting the survival and
proliferative capacity of energy-deprived cancer cells, signi-
fying an important compensatory role for AMPK to support
cell homeostasis via PTEN-mediated activation of Akt signaling.
Further studies are needed to determine the physiological func-
tions of enhanced NO signaling across different disease states,
but the reaction between NO and PTEN forms a nexus
that opens up unique therapeutic opportunities for targeting
dysregulated protein S-nitrosylation for a substantial fraction of
tumors growing under conditions of energy deprivation.
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Antibodies
Rabbit polyclonal anti-Akt Cell Signaling Technology Cat#9272; RPID: AB_329827
Rabbit monoclonal anti-phospho-Akt
(Ser473)
Cell Signaling Technology Cat#4060; RPID: AB_2315049
Rabbit monoclonal anti-GSK-3alpha/beta Cell Signaling Technology Cat#5676; RPID: AB_10547140
Rabbit monoclonal anti-phospho-GSK-
3alpha/beta (Ser21/9)
Cell Signaling Technology Cat#8566; RPID: AB_10860069
Rabbit monoclonal anti-PRAS40 Cell Signaling Technology Cat#2691; RPID: AB_2225033
Rabbit monoclonal anti-phospho-PRAS40
(Thr246)
Cell Signaling Technology Cat#2997; RPID: AB_2258110
Rabbit polyclonal anti-NDRG1 Cell Signaling Technology Cat#5196; RPID: AB_10626626
Rabbit monoclonal anti-phospho-NDRG1
(Thr346)
Cell Signaling Technology Cat#5482; RPID: AB_10693450
Rabbit monoclonal anti-p44/42 MAPK
(Erk1/2)
Cell Signaling Technology Cat#9102; RPID: AB_330744
Rabbit monoclonal anti-phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204)
Cell Signaling Technology Cat#9101; RPID: AB_331646
Rabbit polyclonal anti-4E-BP1 Cell Signaling Technology Cat#9452; RPID: AB_10693791
Rabbit monoclonal anti-phospho-4E-BP1
(Thr37/Thr46)
Cell Signaling Technology Cat#2855; RPID: AB_560835
Rabbit polyclonal anti-rabbit polyclonal
anti-phospho-4E-BP1 (S65)
Cell Signaling Technology Cat#9451; RPID: AB_330947
Mouse monoclonal anti-S6 Ribosomal
Protein
Cell Signaling Technology Cat#2317; RPID: AB_10694551
Rabbit polyclonal anti-phospho-S6
Ribosomal Protein (Ser235/236)
Cell Signaling Technology Cat#2211; RPID: AB_331679
Rabbit monoclonal anti-phospho-S6
Ribosomal Protein (Ser240/244)
Cell Signaling Technology Cat#5364; RPID: AB_10694233
Rabbit monoclonal anti-EGF Receptor Cell Signaling Technology Cat#4267; RPID: AB_2246311
Rabbit monoclonal anti-FoxO3a Cell Signaling Technology Cat#2497; RPID: AB_836876
Rabbit polyclonal anti-phospho-FoxO3a
(Ser253)
Cell Signaling Technology Cat#9466; RPID: AB_2106674
Rabbit polyclonal anti-HSP70 Cell Signaling Technology Cat#4872; RPID: AB_10693928
Rabbit monoclonal anti-PTEN Cell Signaling Technology Cat#9559; RPID: AB_10695541
Rabbit polyclonal anti-AMPK-alpha Cell Signaling Technology Cat#2532; RPID: AB_330331
Rabbit monoclonal anti-phospho-AMPK-
alpha (Thr172)
Cell Signaling Technology Cat#2535; RPID: AB_331250
Rabbit monoclonal anti-Acetyl-CoA
Carboxylase
Cell Signaling Technology Cat#3676; RPID: AB_10694239
Rabbit monoclonal anti-phospho-Acetyl-
CoA Carboxylase (Ser79)
Cell Signaling Technology Cat#11818
Rabbit polyclonal anti-NOS (pan) Cell Signaling Technology Cat#2977; RPID: AB_2236063
Rabbit monoclonal anti-phospho-eNOS
(Ser1177)
Cell Signaling Technology Cat#9570; RPID: AB_823493
Mouse monoclonal anti-Myc epitope tag Cell Signaling Technology Cat#2276; RPID: AB_10693333
Mouse monoclonal anti-Parkin Santa Cruz Biotechnology Cat#sc-32282; RPID: AB_628104
Mouse monoclonal anti-PTEN Santa Cruz Biotechnology Cat#sc-7974; RPID: AB_628187
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Mouse monoclonal anti-PTEN Dako Cat# M3627; RPID: AB_2174185
Mouse monoclonal anti-phospho-eNOS
(Ser632)
Abcam Cat#ab76199; RPID: AB_1523551
Mouse monoclonal anti-S-nitrosocysteine Abcam Cat#ab94930; RPID: AB_10697568
Mouse monoclonal anti-beta Actin Abcam Cat#ab6276; RPID: AB_2223210
Mouse monoclonal anti-mono- and
polyubiquitinylated conjugates
Enzo Life Sciences Cat#BML-PW8810; RPID: AB_10541840
Mouse monoclonal anti-HA.11 epitope tag BioLegend Cat#901501; RPID: AB_2565006
Rabbit polyclonal anti-Parkin ThermoFisher Cat#PA1-38412
Chemicals, Peptides, and Recombinant Proteins
BKM120 (NVP-BKM120, Buparlisib) pan-
PI3K inhibitor
Selleck Chemicals Cat#S2247; CAS: 944396-07-0
BEZ235 (NVP-BEZ235, Dactolisib) dual
PI3K and mTOR inhibitor
Selleck Chemicals Cat#S1009; CAS: 915019-65-7
MK-2206 AKT inhibitor Selleck Chemicals Cat#S1078; CAS: 1032350-13-2
Rapamycin (Sirolimus) mTOR inhibitor Selleck Chemicals Cat#S1039; CAS: 53123-88-9
Trametinib (GSK1120212) MEK inhibitor Selleck Chemicals Cat#S2673; CAS: 871700-17-3
Torin 1 mTOR inhibitor Tocris Bioscience Cat#4247; CAS: 1222998-36-8
PD 0325901 MEK inhibitor Tocris Bioscience Cat#4192; CAS: 391210-10-9
Staurosporine Sigma-Aldrich Cat#S4400; CAS: 62996-74-1
Menadione Sigma-Aldrich Cat#M5625; CAS: 58-27-5
2-Deoxy-D-glucose (2-DG) Sigma-Aldrich Cat#D8375; CAS: 154-17-6
Sodium dichloroacetate (DCA) Sigma-Aldrich Cat#347795; CAS: 2156-56-1
Glutathione reduced ethyl ester Sigma-Aldrich Cat#G1404; CAS: 92614-59-0
L-Buthionine-sulfoximine Sigma-Aldrich Cat#B2515; CAS: 83730-53-4
Carboxy-PTIO Sigma-Aldrich Cat#C221; CAS: 148819-94-7
D-Glucose Sigma-Aldrich Cat#G8270; CAS: 50-99-7
Oligomycin Sigma-Aldrich Cat#75351; CAS: 579-13-5
MG-132 Sigma-Aldrich Cat#M8699; CAS: 1211877-36-9
N-Ethylmaleimide Sigma-Aldrich Cat#E3876; CAS: 128-53-0
Protein G Sepharose, Fast Flow Sigma-Aldrich Cat#P3296
3H-myo-inositol PerkinElmer Cat#NET1168001MC
Puromycin InvivoGen Cat#ant-pr-5b
Blasticidin InvivoGen Cat#ant-bl-1
991 AMPK allosteric activator Xiao et al., 2013 N/A
Sulforhodamine B (SRB) Sigma-Aldrich Cat#S1402; CAS: 3520-42-1
Critical Commercial Assays
Seahorse XF Cell Mito Stress Kit Agilent Cat#103015-100
CellTiter96 AQueous non-radioactive cell
proliferation Assay
Promega Cat#G5421
Caspase-Glo 3/7 Assay Promega Cat#G8090
ROS-Glo H2O2 Assay Promega Cat#G8820
Nitric Oxide Assay Kit Abcam Cat#ab65327
GSH/GSSG-Glo Assay kit Promega Cat#V6611
Nitric Oxide Synthase (NOS) Activity
Assay Kit
BioVision Cat#K205-100
Experimental Models: Cell Lines
HCT116 PTEN+/+ cells Lee et al., 2004 N/A
HCT116 PTEN/ cells Lee et al., 2004 N/A
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MCF10A PTEN+/+ cells Horizon Cat#HD 101-006
MCF10A PTEN/ cells Horizon Cat#HD 101-006
JIMT-1 cells DSMZ Cat#ACC 589
HCT116 parental cells ATCC Cat#CCL-247
293T ATCC Cat#CRL-3216
PC-3 ATCC Cat#CRL-1435
H460 ATCC Cat#HTB-177
H1299 ATCC Cat#CRL-5803
U-138 MG ATCC Cat#HTB-16
MDA-MB-134 ATCC Cat#HTB-23
BT-474 ATCC Cat#HTB-20
UACC-812 ATCC Cat#CRL-1897
MCF7 ATCC Cat#HTB-22
Hs 578T ATCC Cat#HTB-126
SK-BR-3 ATCC Cat#HTB-30
AU565 ATCC Cat#CRL-2351
BT-20 ATCC Cat#HTB-19
ZR-75-30 ATCC Cat#CRL-1504
Experimental Models: Organisms/Strains
Mouse: C57BL/6J Charles River Stock No: 000664
Mouse: Pten+/ Di Cristofano et al., 1998 N/A
Mouse: Park2/ Itier et al., 2003 N/A
Mouse: NOD.CB17-Prkdcscid/J Charles River Stock No: 001303
Recombinant DNA
TRC Lentiviral eGFP shRNA positive control Dharmacon Cat#RHS4459
TRC Human PARK2 shRNA 1 Dharmacon Cat# TRCN0000000283
TRC Human PARK2 shRNA 2 Dharmacon Cat# TRCN0000000285
pLenti6/UbC/V5-DEST-empty vector ThermoFisher Cat#V49910
pLenti6/UbC/V5-DEST-PARK2-WT This study N/A
pLenti6/UbC/V5-DEST-PARK2-C431S This study N/A
pLV430G-oFL-T2A-eGFP Green et al., 2015 N/A
pRK5-Myc-PTEN-WT Song et al., 2011 N/A
pRK5-Myc-PTEN-C83S This Study N/A
HA-Ubiquitin Addgene Cat#18712
pHR-SIN-PTEN-WT Addgene Cat#30370
pHR-SIN-PTEN-C83S This Study N/A
Sequence-Based Reagents
Silencer Select Non-targeting Negative
Control
ThermoFisher Cat#4390843
Silencer Select Pre-Designed siRNA
against PRKAA1 (AMPKa1): siRNA ID: s100
ThermoFisher Cat#4392420
Silencer Select Pre-Designed siRNA
against PRKAA2 (AMPKa2): siRNA ID:
s11056
ThermoFisher Cat#4390824
LentiCRISPR v2 Addgene Cat#52961
PARK2 sgRNA CRISPR/Cas9 All-in-One
Lentivector (Human) (Target 3)
Applied Biological Materials Cat#K1594608
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Primers for human PARK2 (F:
GGTAGATCAATCTACAACAGCTTTTATG,
R: TGCACTAGTCCCAGGGCA)
Hedrich et al., 2001 N/A
Primers for human PTEN (F:
CAAGATGATGTTTGAAACTATTCCAATG,
R: CCTTTAGCTGGCAGACCACAA)
Kim et al., 2004 N/A
Primers for human 18S (F:
GTGGAGCGATTTGTCTGGTT, R:
CGCTGAGCCAGTCAGTGTAG)
Leonard et al., 2003 N/A
Software and Algorithms
R statistical software (ver 3.2.3) and
Bioconductor (ver 3.4)
The R Project https://www.r-project.org/
https://www.bioconductor.org/
Oncomine (ver 4.5) ThermoFisher https://www.oncomine.org/
GISTIC Broad Institute http://portals.broadinstitute.org/tcga/home
MultiQuant (ver 1.1) SCIEX https://sciex.com/products/software/
multiquant-software
KM plotter Sza´sz et al., 2016 http://kmplot.com/analysis/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, George
Poulogiannis (george.poulogiannis@icr.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Pten+/ heterozygous mice (Di Cristofano et al., 1998) were bred with mice harboring a targeted knockout of Park2 exon 3 (Itier et al.,
2003). All mice were previously backcrossed over ten generations and maintained in a C57BL/6 background and they were geno-
typed by PCR for Pten and Park2 alleles as described previously (Di Cristofano et al., 1998; Itier et al., 2003). Tumor-bearing mice
were euthanized and subjected to whole-body histological analysis. Normal and tumor tissues were fixed in 4% PFA, embedded
in paraffin, sectioned, and subjected to hematoxylin and eosin (H&E) staining for pathological evaluation. Survival analyses were per-
formed using Kaplan–Meier curves and the Log-rank test. Six- to eight-week old NOD.CB17-Prkdcscid/J mice were injected via the
retrobulbar sinus with 200 ml cell suspension (1x106 cells) of GFP flow-sorted luciferase labeled (pLV430G-oFL-T2A-eGFP) H1299
cells expressing pLenti6∕UbC∕V5-DEST- empty vector or PARK2. Development of metastases was monitored by luciferin injection
and bioluminescence imaging at 3 and 4 weeks post-injection. Bioluminescence (BLI) signal intensities were determined by using the
region of interest (ROI) tool in Living Image Software (PerkinElmer). After the last imaging session the mice were euthanized and the
lungs were surgically removed and inflated with 4% formalin in PBS. Lung sections, 5 mm, were subjected to H&E staining and the
number of lung tumor nodules was counted using a dissection microscope. All mice were maintained according to NIH-approved
institutional animal care guidelines and the study was approved by the Institutional Committee at the Beth-Israel Deaconess Medical
Center.
Cell Culture
293T and PC3 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml
streptomycin. HCT116 parental and isogenic PTEN null cell lines (Lee et al., 2004) were cultured in McCoy’s 5A, H460 and H1299
cells in RPMI, and U138 cells in DMEM-F12, all supplemented as above. The breast cancer cell lines MDA-MB-134, BT-474,
UACC-812, MCF-7, Hs-578T, SK-BR-3, AU-565, BT-20 and JIMT-1 were cultured in DMEM, and the ZR-75-30 cells in RPMI, all sup-
plemented as above. MCF10A parental and isogenic PTEN null cells were cultured in DMEM-F12 supplemented with 5% horse
serum (HS) (ThermoFisher, 16050-122), 20 ng/ml EGF (PeproTech, AF-100-15), 0.5 mg/ml hydrocortisone (Sigma-Aldrich,
H0888), 100 ng/ml cholera toxin (Sigma-Aldrich, C8052), 10 mg/ml insulin (Sigma-Aldrich, I1882), supplemented with penicillin and
streptomycin as above. All cell lines were maintained at 37C in a humidified incubator with 5% CO2 and were tested and confirmed
to be negative for mycoplasma infection. For glucose starvation experiments, cells were washed twice with PBS and then incubated
in DMEMwithout glucose and sodium pyruvate supplementedwith 10%dialyzed FBS for 6 hr. For treatment with the allosteric AMPKMolecular Cell 65, 999–1013.e1–e7, March 16, 2017 e4
activator 991 (Xiao et al., 2013), cells were serum-starved for 2 hr prior to 991 treatment for 5 hr. All cell lines used in the study were
submitted to Eurofins Genomics for autosomal short tandem repeat (STR) authentication.
METHOD DETAILS
Transfections
For lentiviral gene knockdown, pLKO.1 shRNA sequences against human PARK2 orGFP control were transfected in 293T cells using
the FuGENE 6 transfection reagent (Promega, E2691) according to the manufacturer’s protocols. Infected cells were selected in the
presence of 2 mg/ml puromycin (InvivoGen, ant-pr-5b) for at least 4 days. Stably expressing cancer cell lines were established
by infecting with virus encoding human wild-type PARK2, the E3 ligase dead C431S mutant or empty vector in the
pLenti6∕UbC∕V5-DEST backbone (ThermoFisher, V49910). Infected cells were selected in the presence of 2-10 mg/ml blasticidin
(InvivoGen, ant-bl-1) for 2 weeks. For stable expression of luciferase and GFP, H1299 cells were infected with pLV430G-oFL-
T2A-eGFP (Green et al., 2015), a lentivirus expressing the luciferase gene cloned in a eGFP expressing vector (gift from Dr Tina
Yuan, Dana-Farber Cancer Institute, Harvard Medical School, Boston), and GFP-positive cells were sorted by flow cytometry
1 week after infection. H460 cells were transfected with PARK2 sgRNA CRISPR/Cas9 All-in-One Lentivector Target 3 (Applied Bio-
logical Materials, K1594608) or control LentiCRISPR v2 according to the manufacturer’s instructions. Infected cells were selected in
the presence of 2 mg/ml puromycin for 4 days and isolation of PARK2 clonal deletion mutants was validated by immunoblotting anal-
ysis and DNA sequencing.
Immunoblot Analysis
Cells were washed with ice-cold PBS and lysed on ice for 30 min with cell lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, supplemented freshly with a protease and phosphatase inhibitor cocktail (5872,
Cell Signaling Technology), 10nMCalyculin A (Cell Signaling Technology, 9902) and 1 mMDTT (ThermoFisher, R0861). Lysates were
subjected to centrifugation at 12,000 g for 10 min at 4C and protein concentrations were determined using the Bradford assay (Bio-
Rad, 5000006). Protein lysates were boiled for 10 min and subjected to SDS-PAGE electrophoresis. Densitometry was calculated
using the Image Lab Software 5.2.1 (Bio-Rad).
Immunohistochemistry
TheGBM tissuemicroarray (TMA) was prepared and characterized as described previously from the Tumor Tissue Bank at University
Health Network, University of Toronto (Agnihotri et al., 2012). Briefly, the TMA was de-waxed in xylene followed by rehydration in a
standard alcohol series. Antigen retrieval was by pressure cooking for 20min in citrate buffer (pH 6.0), followed by blocking of endog-
enous peroxidase in 0.3% H2O2. Antibody incubation was performed using the ABC reagent kit (Vector Labs, PK-6100) as per man-
ufacturers instructions. Briefly, Parkin antibody (ThermoFisher, PA1-38412) was diluted 1:100 in antibody diluent and added to the
slides and incubated overnight at 4C. Detection was performed using biotinylated secondary antibodies for 30min, the ABC reagent
kit and 3,30-Diaminobenzidine chromogen. Sections were counter-stained with hematoxylin (ThermoFisher, 008001) for 30 s, dehy-
drated in 70, 80 and 100% ethanol, briefly washed in xylene and mounted in Permount (ThermoFisher, SP-15). For PTEN and phos-
pho-AKT immunohistochemistry of mouse tumor sections, antigen retrieval was carried out bymicrowave heating for 20min in citrate
buffer (pH 6.0). Anti-PTEN (Dako, M3627) and anti-phospho-Akt (Ser473) (Cell Signaling Technology, 4060) antibodies were applied
at dilutions of 1:200 and 1:50 respectively. PTEN and phospho-Akt IHC staining intensity was graded as 0 (negative), 1 (weak), 2
(moderate), and 3 (strong). Images were captured on a Nikon E-600 microscope and analyzed using Nikon ACT-1 software.
PTEN Phosphatase Activity Assay
For PTEN phosphatase activity assay, PTEN-transfected cells [pRK5-Myc-PTEN-WT, (Song et al., 2011)] were lysed in lysis buffer
containing protease and phosphatase inhibitors in the absence of DTT. PTEN was immunoprecipitated from 1 mg of cell lysates
and the PTEN phosphatase activity was measured using a PTEN activity ELISA kit (Echelon Biosciences Inc, K-4700), following
the manufacturer’s instructions. Where indicated, PTEN immunoprecipitates were treated with 50 mM DTT at 4C for 30 min prior
to measuring PTEN phosphatase activity.
Detection of S-Nitrosylated PTEN
S-nitrosylation of PTEN was detected using the 2,3-diaminonaphthalene (DAN) assay. Briefly, PTEN transfected cells (pRK5-Myc-
PTEN-WT) were lysed in lysis buffer containing protease and phosphatase inhibitors and 40 mM N-ethylmaleimide in the absence
of DTT. PTEN was immunoprecipitated from equal volume of the diluted cell lysates containing 1 mg of soluble protein. The immu-
noprecipitates were washed twice with lysis buffer and twice with PBS. The pellet was resuspended in 500 mL of PBS and 100 mM
HgCl2 and 100 mMDANwas added. The samples were incubated in the dark at room temperature (RT) for 30 min and 1MNaOHwas
added. The generated fluorescent triazole from the reaction of DAN with the NO released from PTEN was measured using an exci-
tation wavelength of 375 nm and an emission wavelength of 450 nm. As a negative control, the PTEN antibody alone in lysis buffer
was immunoprecipitated and the resulting background fluorescence intensity was subtracted from each sample. S-nitrosylated
PTEN was confirmed by immunoblotting of immunoprecipitated PTEN with anti-S-nitrosocysteine antibody (Abcam, ab94930),e5 Molecular Cell 65, 999–1013.e1–e7, March 16, 2017
under non-reducing conditions. For non-reducing SDS-PAGE, b-mercaptoethanol was omitted from the loading buffer and samples
were not boiled.
In Cell PTEN Ubiquitination Assay
Cellular assays to measure PTEN polyubiquitination were performed as described previously (Gupta et al., 2016). Briefly, cells were
transfected with vectors encoding wild-type PTEN in the pRK5-Myc vector and HA-Ub and lysed in the presence of 40 NEM and
supplemented freshly with a protease and phosphatase inhibitor cocktail. Equal volume of the diluted cell lysates containing 1mg
of soluble protein was incubated with 1 mg mouse monoclonal anti-PTEN (Santa Cruz Biotechnology, sc-7974) or 2 mg mouse
anti-HA (BioLegend, 901501) antibodies pre-coupled with protein G Sepharose beads (Sigma-Aldrich, P3296) and incubated at
RT for 2 hr rotating. Beads were washed four times in immunoprecipitation buffer (50 mmol/L Tris, pH 7.6, 100 mmol/L NaCl,
2 mmol/L EDTA, and 0.2% Nonidet P-40) and the bound proteins were released by boiling in SDS-PAGE sample buffer for
10 min, prior to SDS-PAGE analysis and immunoblotting with the indicated antibodies.
3H-Labeling of Phosphoinositides and HPLC Analysis
Subconfluent cells in 10-cm dishes were labeled in 8 mL of inositol-free DMEM and 10% dialyzed FBS supplemented with 160 mCi
3H-myo-inositol (PerkinElmer, NET1168001MC, specific activity = 20.1 Ci/mmol) for 24 hr. Deacylated phosphoinositides were
resolved by HPLC using an Agilent 1200 Quaternary system, and radioactivity detected in-line using a Packard Flo-one Radiomatic
detector. HPLC Buffer A is 1 mM EDTA, and Buffer B is 1 mM EDTA and 1 M NaH2PO4. An Agilent Zorbax SAX column (5 mm, 4.6 X
250mm) was eluted by gradient program (from 100%A to 2%B at 1 min, 14%B at 30 min, 30%B at 31 min, 66% at 60min, 100%B
at 85 min, 100% A at 86 min, and hold at 100% A until 110 min) at a flow rate of 1 ml/min. PI(3,4)P2, PI(3,4,5)P3 standards were pre-
pared by reacting PI3K with PI4P and PI5P, respectively and [g-32P]ATP.
MTS and Caspase-3/7 Assays
Cell viability was assessed using the CellTiter96 AQueous non-radioactive cell proliferation assay [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] (Promega, G5421) according to the manufacturer’s
protocol. Caspase-3/7 activities were measured using the Caspase-Glo 3/7 assay (Promega, G8090) following treatment with 50
or 100 nM staurosporine (Sigma-Aldrich, S4400) for 1 hr. For both cell viability and caspase 3/7 assays, HCT116 cells were seeded
at 3x104 cells/well in a 96-well plate and incubated overnight before treatment.
Cell Proliferation and Cell Migration Assays
Proliferation kinetics of H1299, PC3, HCT116 PTEN+/+ and HCT116 PTEN/ cells transfected with pLenti6/UbC/V5-DEST-PARK2-
WT, PARK2-C431Smutant or empty vector were determined using the Sulforhodamine B (SRB) (Sigma-Aldrich, S1402) assay over a
period of 5 days. The samemethodwas applied for shGFP and shPARK2-expressing PC3 cells transfectedwith pHR-SIN-PTEN-WT,
PTEN-C83S and control empty vector. Briefly, 2x103 cells were seeded in a 96-well plate in triplicate and allowed to adhere for 24 hr
(Day 0). Cells were fixed at days 0, 1, 3 and 5 as follows: they were fixed with 10% trichloracetic acid at 4C for 60 min and washed 4x
with 100 mL dH2O. After being left to dry at RT, the cells were stained for 10min with 0.4% (w/v) SRB dissolved in 1% acetic acid, and
protein-bound dye was extracted with 10 mM unbuffered Tris base pH 10.5. Absorbance was determined at 510 nm using a 96-well
microplate reader and data presented indicate the average number of triplicate experiments ± standard error of the mean (SEM).
For cell migration assays, cells were starved overnight in 0.5% FBS and 5x104 cells/well were seeded in 24-well transwell cham-
bers (Corning, Lowell, MA, USA; 8 mm pore size) in a total volume of 300 ml 0.5% FBS-media. 750 ml of media (supplemented with
10%FBS) were added to the bottom of the transwells and the plates were returned to 37C for 24 hr incubation. The transwell inserts
were washed twice in PBS and cells were fixed in 10% trichloroacetic acid (TCA) for 1 hr. The TCA containing media was removed
and the inserts were washed 3x in H2O. Cells were stained in 0.4% (w/v) SRB dissolved in 1% acetic acid for 10min. The inserts were
washed 3x in 1%acetic acid and the cells on the top of the filter were removed using a cotton swab.Migrated SRB-stained cells in the
bottom of the transwell inserts were counted under a light microscope at 20x magnification in 5 fields/well.
Cytotoxicity and Clonogenic Assays
For determination of the IC50 values of 2-DGandDCA, shGFP- or shPARK2-expressing PC3 cells were co-transfectedwith pHR-SIN-
PTEN-WT, PTEN-C83S and control empty vector. 48 hr post transfection, the cells were seeded at 5x103 cells/well in a 96-well plate
and treated with various concentrations of 2-DG (0.5-50 mM) or DCA (5-80 mM) for 72 hr followed by SRB staining. For clonogenic
assays, cells were plated at 13 102 cells/well in 24-well plates and treated with 10 mMDCA or 0.5 mM 2-DG. After 10 days, colonies
were stained with a Crystal Violet solution (0.5% Crystal Violet, Sigma, 30% ethanol and 3% formaldehyde) and were counted in a
GelCount (Oxford Optronix). Every experiment was performed in triplicate and data are presented as mean values ± SEM.
Real-Time qRT-PCR
Total RNA was extracted using the ReliaPrep RNA cell miniprep system (Promega, Z6010) according to the manufacturer’s instruc-
tions. Reverse transcription and real-time PCR reactions were carried out using the QuantiTect reverse transcription kit (QIAGEN,
205310) and SYBR select master mix (ThermoFisher, 4472908) respectively, using the TProfessional ThermoCycler from Biometra.Molecular Cell 65, 999–1013.e1–e7, March 16, 2017 e6
The data presented are the mean values obtained ± SEM from triplicate reactions. Primer sequences used are as follows; Human
PARK2, sense: TCAATCTACAACAGCTTTTATG, anti-sense: TGCACTAGTCCCAGGGCA (Hedrich et al., 2001), Human PTEN,
sense: CAAGATGATGTTTGAAACTATTCCAATG, anti-sense: CCTTTAGCTGGCAGACCACAA (Kim et al., 2004), Human 18S, sense:
GTGGAGCGATTTGTCTGGTT, anti-sense: CGCTGAGCCAGTCAGTGTAG (Leonard et al., 2003).
ROS, NO, GSH/GSSG and NOS Activity Measurements
H2O2 levels were measured using the ROS-Glo H2O2 assay (Promega, G8820) according to the manufacturer’s instructions. Briefly,
1x104 shGFP control and shPARK2-expressing cells were seeded in a 96-well plate and incubated at 37C and 5% CO2 for 18 hr.
Cells were washed with PBS and treated in Hank’s BSS medium containing 20 mM menadione (Sigma-Aldrich, M5625) in the pres-
ence of 20 ml 125 mMH2O2 substrate (provided in the kit). Following incubation at 37
C for 2 hr, 100 ml of ROS-Glo detection solution
was added to thewells and the plate was incubated for 20min at RT. Luminescence was determined with amicroplate reader and the
average relative light units (RLU) ± SEM of triplicate data are reported.
Nitric oxide (NO) levels were detected using the Nitric Oxide Assay Kit (abcam, ab65327) according to themanufacturer’s protocol.
Briefly, shGFP and shPARK2-expressing cells were grown in regular culture medium for 24 hr. After washing with cold PBS, 2x106
cells were resuspended in 500 ml assay buffer and homogenized quickly by pipetting up and down a few times. The samples were
centrifuged for 5min at 4Cat top speed to remove any insolublematerial. Triplicate 75 ml aliquots of the supernatant were transferred
to a 96-well plate and 5 ml of enzyme cofactor and 5 ml of nitrate reductase were added to each of the reaction wells. The plate was
incubated at RT for 3 hr and 5 ml of enhancer was added to each well, before further incubation for 30min at RT. 5 ml of the DAN probe
was added to eachwell, the plate was incubated at RT for 10min and 5 ml of NaOHwas added before final incubation at RT for 10min.
Fluorescence was determined with a microplate reader at Ex/Em = 360/450nm. All reagents were provided in the kit. GSH:GSSG
levels weremeasured using the GSH/GSSG-Glo Assay kit (Promega, V6611) and nitric oxide synthase (NOS) activity was determined
using the NOS activity assay kit (BioVision, K205-100) according to the manufacturer’s protocol.
Mitochondrial Flux Analysis
PARK2 andGFP stable knockdown cells were plated at 2x104/well in a 96-well Seahorse cell culture microplate and incubated over-
night. The next morning, culture media was replaced with pH-adjusted (pH = 7.4 ± 0.1) bicarbonate-free DMEMwith 10mMGlucose,
1 mM sodium pyruvate and 2 mM L-Glutamine and the plate was incubated at 37C for 1 hr in a non–CO2 incubator. Oxygen
consumption rates were measured using the Seahorse XF Cell Mito Stress Kit (Agilent, 103015-100) on a XFe96 Analyzer. 2 mM
Oligomycin, 0.5 mM FCCP, and 0.5 mM rotenone/antimycin (R/A) were used for all conditions. Cell numbers were normalized using
Cyquant (ThermoFisher, C35012).
Tandem Mass Spectrometry
Metabolite levels were determined by targeted liquid-chromatography tandem mass spectrometry (LC-MS/MS) analysis as
described previously (Yuan et al., 2012). Briefly, 48 hr prior to each experiment, 2.5x105 HCT116 cells expressing shGFP or shPARK2
were seeded in 6-cm dishes. Themedia for each plate was replaced 2 hr prior to metabolite extraction and after aspiration, 4 mL pre-
chilled (at 80C) methanol was added to the cells on dry ice for 15 min. Cell extracts were collected into 15 mL conical tubes and
centrifuged for 5 min at 4200 rpm. Solvent in the resulting supernatant was evaporated using a centrifugal vacuum evaporator
(‘‘SpeedVac’’) and samples were re-suspended in 20 mL HPLC-grade water for mass spectrometry. 8 mL were injected and analyzed
using a Prominence UFLC HPLC system (Shimadzu) for hydrophilic interaction liquid chromatography (HILIC), coupled to a QTRAP
5500 hybrid triple quadrupole/linear ion trap mass spectrometer (SCIEX) operated in the selected reaction monitoring (SRM) mode.
Peak areas of LC-SRM-MS traces for each metabolite were integrated using the MultiQuant v1.1 software (SCIEX).
QUANTIFICATION AND STATISTICAL ANALYSIS
Bioinformatic Analysis
GISTIC (Genomic Identification of Significant Targets in Cancer) analyses were performed on DNA copy number data from the SNP
pipeline version 3.0. 9,863 tumor samples across 28 cancer types were selected for this analysis using the 2015-06-01 stddata
TCGA/GDAC tumor sample sets from FireHose, and the frequencies ofPARK2DNA copy number changeswere plotted using a polar
histogram. The Oncomine cancer profiling database was used to analyze PARK2 mRNA expression across 13,499 cancerous and
2,708 normal tissue specimens from 125 independent microarray datasets representing 27 different cancer types. The degree of
PARK2 mRNA underexpression (R0.5 andR 1-log2-fold change in tumor versus normal) was plotted across all tumor types. Ka-
plan-meier analysis in Figure S1C was performed using the KM plotter (Sza´sz et al., 2016). Student’s t test and one- or two-way
ANOVA were used to evaluate the statistical significance among different variables as indicated in the respective figure legends;
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